Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting

Ana-Maria Orbai; Philip J Mease; Maarten de Wit; Umut Kalyoncu; Willemina Campbell; William Tillett; Lihi Eder; Musaab Elmamoun; Oliver FitzGerald; Dafna D Gladman; Niti Goel; Laure Gossec; Chris A Lindsay; Ingrid Steinkoenig; Philip S Helliwell; Neil J McHugh; Vibeke Strand; Alexis Ogdie

doi:10.3899/jrheum.160116

Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting

J Rheumatol. 2016 May;43(5):965-9. doi: 10.3899/jrheum.160116.

Authors

Ana-Maria Orbai¹, Philip J Mease¹, Maarten de Wit¹, Umut Kalyoncu¹, Willemina Campbell¹, William Tillett¹, Lihi Eder¹, Musaab Elmamoun¹, Oliver FitzGerald¹, Dafna D Gladman¹, Niti Goel¹, Laure Gossec¹, Chris A Lindsay¹, Ingrid Steinkoenig¹, Philip S Helliwell¹, Neil J McHugh¹, Vibeke Strand¹, Alexis Ogdie¹

Affiliation

¹ From the Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA; VU Medical Centre, Amsterdam, The Netherlands, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA; Department of Internal Medicine, Division of Rheumatology, Hacettepe University Ankara, Ankara, Turkey; Toronto Western Hospital, Toronto, Ontario, Canada; Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Rheumatology, St. Vincent's University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; University of Toronto, Krembil Research Institute, Psoriatic Arthritis Program, University Health Network, Toronto, Ontario, Canada; Quintiles, Duke University School of Medicine, Durham, North Carolina, USA; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Cleveland Clinic, Cleveland, Ohio, USA; University of Leeds, Leeds, UK, and Bradford Hospitals National Health Service (NHS) Foundation Trust, Bradford, UK; Division of Immunology, Stanford University, Palo Alto, California, USA; University of Pennsylvania, Philadelphia, Pennsylvania, USA.A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; U. Kalyoncu, MD, Division of Rheumatology, Johns Hopkins University and Department of Internal Medicine, Division of Rheumatology, Hacettepe University Ankara; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; W. Tillett, BSc, MB, ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; L. Eder, MD, PhD, Toronto We

Abstract

The GRAPPA-OMERACT psoriatic arthritis (PsA) working group is in the process of updating the PsA core domain set to improve and standardize the measurement of PsA outcomes. Work streams comprise literature reviews of domains and outcome measurement instruments, an international qualitative research project with PsA patients to generate domains important to patients, outcome measurement instrument assessment, conduct of domain consensus panels with patients and physicians, and evidence-based selection of instruments. Patient research partners are involved in each of the projects. The working group will present findings and seek endorsement for the new PsA core domain set, outcome measurement set, and research agenda at the OMERACT meeting in May 2016.

Keywords: CORE SET; OUTCOME MEASURES; PSORIATIC ARTHRITIS.

MeSH terms

Arthritis, Psoriatic / diagnosis*
Arthritis, Psoriatic / drug therapy
Humans
Outcome Assessment, Health Care*
Severity of Illness Index

Abstract

MeSH terms

Grants and funding